ARWR - Arrowhead to get $40M milestone as Takeda starts fazirsiran dosing in liver disease trial

2023-04-04 08:18:16 ET

• Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) will receive a $40M milestone payment from Takeda Pharmaceutical ( NYSE: TAK ) as the Japanese patient dosed the first patient in a phase 3 trial of fazirsiran to treat alpha-1 antitrypsin deficiency associated liver disease (AATD-LD).
• The company noted that fazirsiran (TAK-999/ARO-AAT) is an investigational RNA interference (RNAi) therapy aimed to reduce the production of mutant alpha-1 antitrypsin protein (Z-AAT) as the first potential therapy for AATD-LD.
• AATD is a genetic disease in which there is low production of a protein called Alpha-1-antitrypsin (AAT). This protein is produced in the liver and protects the body's tissues from damage by infection-fighting agents released by the immune system. AATD can cause lung and liver diseases.
• The phase 3 trial, dubbed REDWOOD, will enroll 160 adults and will evaluate fazirsiran versus placebo.
• ARWR +1.76% to $26.01 premarket April 4

For further details see: